Check Eligibility

What Happens When You Stop Mounjaro? Maintenance and Discontinuation Explained (2026 UK Guide)

A clinical guide to stopping Mounjaro — what to expect, how to minimise weight regain, and the difference between discontinuation and a structured maintenance plan.

Moazma Ahmed Prescriber
Medically reviewed by
Moazma Ahmed, MPharm
Pharmacist Independent Prescriber · GPhC No. 2069977
Lead Prescriber, Live Well Weight Loss

Last medically reviewed

23 April 2026

Last updated

23 April 2026

Next review due

23 October 2026

Quick answer

When you stop Mounjaro, the appetite suppression effect ends within weeks and most patients experience some weight regain. The amount and pace varies significantly between individuals.

 

– Most patients regain a meaningful proportion of lost weight within 12 months of stopping, particularly if treatment ends abruptly without a maintenance plan.

 

– Trial data suggests patients who stopped tirzepatide regained about half their lost weight within a year on average, though individual outcomes vary widely.

 

– A structured maintenance plan — continuing on a lower dose rather than stopping entirely — is now considered best practice for many patients and is supported by emerging clinical evidence.

 

– Tapering off rather than stopping abruptly can reduce side effects and help manage the transition, though there is no formal pharmacological taper required.

 

– Sustained weight maintenance after stopping is possible but requires deliberate effort: continued lifestyle change, regular monitoring, and sometimes alternative interventions.

 

This article explains what happens physically when you stop, how to plan discontinuation safely, and what options exist for ongoing weight maintenance.

What actually happens in your body when you stop Mounjaro?

Mounjaro (tirzepatide) works by activating GIP and GLP-1 receptors, which suppress appetite, slow gastric emptying, and improve metabolic markers.
When you stop the injection, those effects fade as the medication clears from your system.

 

Days 1–7 after stopping

 

Tirzepatide has a half-life of approximately 5 days. After your last injection, the drug remains active in your system for several weeks at gradually decreasing levels. In the first week you typically notice no significant changes.

 

Weeks 2–4

Appetite begins to return as drug levels fall. Many patients notice they feel hungrier, can eat larger portions before feeling full, and experience more food cravings — particularly for carbohydrates and processed foods. Some patients describe this as their “old appetite returning.”

 

Weeks 4–12

Without intervention, most patients experience gradual weight regain. The pace depends on dietary habits, physical activity, and individual metabolic factors. Hunger hormones (notably ghrelin) often rebound, sometimes above pre-treatment levels — known as “rebound hunger.”

Months 3–12

Weight regain typically continues, often at a slowing pace. Trial data suggests that without a structured maintenance plan, patients regain approximately 50% of their lost weight within a year of stopping tirzepatide. Some regain less, some regain all of it or more.

 

The key point is that Mounjaro doesn’t permanently change your metabolism. It manages a chronic condition — overweight and obesity — much like blood pressure medication manages hypertension. When you stop, the underlying
biology returns.

Why do most people regain weight after stopping?

Three main reasons drive post-discontinuation weight regain:

1. Appetite hormones return to baseline While on Mounjaro, ghrelin (the “hunger hormone”) and other appetite signals are suppressed. When the medication is stopped, these signals return — sometimes overshooting baseline levels temporarily. Patients often feel hungrier than they did before treatment for a period.

 

2. Metabolic adaptation
Significant weight loss reduces resting energy expenditure (your body uses fewer calories at rest). This adaptation persists after stopping the medication, meaning patients can regain weight on calorie intakes that previously maintained their lower weight.

3. Behavioural drift
Even highly motivated patients often experience gradual drift back toward pre-treatment eating patterns once the medication-driven appetite suppression is gone. Without the medication’s “automatic” portion control, conscious effort is required to maintain the same intake.

This is not a failure of willpower — it’s a predictable physiological response. Understanding it allows for better planning around discontinuation.

 

Should you stop Mounjaro at all?

Many patients reach goal weight or near-goal weight and ask whether they should stop or continue treatment. The clinical answer is increasingly:
don’t think of Mounjaro as a treatment you complete. Think of it as a chronic medication for a chronic condition.

 

Three options to consider:

Continue at the same dose Some patients continue at their treatment dose (often 10mg, 12.5mg, or 15mg) indefinitely. This maintains appetite suppression and minimises weight regain risk but is the most expensive option and may have continued side effect impact.

 

Step down to a maintenance dose Many patients reduce to a lower dose (typically 5mg or 7.5mg) once at goal weight. This reduces cost and side effect burden while preserving most of the appetite control. Emerging evidence supports this approach for many patients.

 

Stop with a structured maintenance plan Patients who choose to stop entirely benefit from a deliberate plan: continued lifestyle support, regular weight monitoring, an early intervention plan if regain begins, and possibly intermittent treatment cycles in the future.

 

The right choice depends on individual goals, financial circumstances, side effect tolerance, and clinical factors. This is one of the most important conversations to have with your prescriber, and it should happen before you reach goal weight, not after weight regain has begun.

Thinking about your maintenance plan?

If you’re approaching goal weight or considering changes to your treatment, contact our pharmacy team to discuss your options. We support patients through maintenance and discontinuation, not just initial weight loss.

Contact Us

What is a maintenance dose and how does it work?

A maintenance dose is a lower dose of Mounjaro continued after the initial weight loss phase. Rather than stopping treatment entirely, you remain on a reduced dose to preserve appetite control and prevent regain.

 

Typical maintenance approaches:

– 5mg maintenance: many patients can maintain at this dose with adequate appetite control and lower cost
– 7.5mg maintenance: a middle ground that retains stronger appetite suppression
– Step-down from a higher dose: some patients gradually reduce from their treatment dose over months

 

What the evidence shows:

 

Long-term trial data on tirzepatide maintenance is still emerging in 2026. The SURMOUNT-4 trial specifically examined what happens when patients
continue versus withdraw from tirzepatide after initial weight loss. Patients who continued the medication maintained their weight loss
substantially better than those who switched to placebo. Patients who stopped regained weight steadily over the following year.

 

Clinical decision-making for maintenance:

 

The choice of maintenance dose involves:

 

– Your weight loss outcomes on the higher dose
– Side effect tolerance
– Cost considerations
– Your stability of weight at goal
– Other clinical factors (e.g. diabetes control, cardiovascular risk)

 

This is not a one-size-fits-all decision. At Live Well Weight Loss, the maintenance conversation typically begins as patients approach their goal weight, not after they’ve stopped. We support patients through the transition, including monitoring weight, adjusting doses if needed, and providing ongoing pharmacist contact.

 

What about tapering off Mounjaro?

Mounjaro doesn’t require formal pharmacological tapering — there’s no withdrawal syndrome and no medical risk to stopping abruptly. However, many patients find a gradual reduction helpful for two reasons:

 

1. Reduced side effect rebound Some patients experience digestive changes when stopping abruptly — increased appetite, altered stool patterns, or rebound nausea. Tapering can soften this transition.

2. Easier behavioural adjustment Stepping down through dose levels gives more time to adjust eating habits, recognise hunger cues returning, and implement maintenance strategies before treatment is fully stopped.

 

A typical taper might look like:

 

– Reduce from 15mg to 10mg for 4–8 weeks
– Reduce to 7.5mg for 4–8 weeks
– Reduce to 5mg for 4–8 weeks
– Either stop or continue indefinitely on 5mg as a maintenance dose

 

This is not a clinical requirement — it’s a practical strategy. Many patients also stop without tapering and manage well with appropriate behavioural support.

The decision should be made in conversation with your prescriber based on your circumstances, goals, and how confident you feel about maintaining weight without medication.

 

How to minimise weight regain after stopping

If you do decide to stop Mounjaro entirely, several strategies can reduce the likelihood and pace of weight regain:

Maintain protein intake. Protein is the most satiating macronutrient and helps preserve lean muscle during and after weight loss. Aim for adequate protein at every meal — this becomes especially important without medication-driven satiety.

Continue resistance training. Muscle mass affects resting metabolic rate. Regular resistance training during and after weight loss helps preserve
muscle and can offset some of the metabolic adaptation that drives regain.

Monitor weight regularly. Weekly or bi-weekly weighing allows you to catch upward drift early, when it’s still small and easier to address. Many patients who succeed in long-term maintenance use regular self-monitoring.

Plan for the appetite return. Anticipate that hunger will increase weeks after stopping. Have strategies in place — meal structure, food choices,
activity levels — that don’t rely on the medication’s appetite suppression.

Consider periodic check-ins. Some patients benefit from staying in touch with their prescriber after stopping, with check-ins at 3, 6, and 12 months. This allows early intervention if weight regain begins.

Plan for treatment cycles if needed. If you stop and regain meaningful weight, restarting Mounjaro is a clinical option, not a failure. Some
patients use the medication in cycles, with treatment phases interspersed with maintenance phases. This should be discussed with a prescriber.

Address underlying drivers. For many patients, weight is influenced by stress, sleep, hormonal factors, or mental health. Addressing these alongside medication and after stopping it improves long-term outcomes.

What is a maintenance dose and how does it work?

A maintenance dose is a lower dose of Mounjaro continued after the initial weight loss phase. Rather than stopping treatment entirely, you remain on a reduced dose to preserve appetite control and prevent regain.

 

Typical maintenance approaches:

– 5mg maintenance: many patients can maintain at this dose with adequate appetite control and lower cost
– 7.5mg maintenance: a middle ground that retains stronger appetite suppression
– Step-down from a higher dose: some patients gradually reduce from their treatment dose over months

 

What the evidence shows:

 

Long-term trial data on tirzepatide maintenance is still emerging in 2026. The SURMOUNT-4 trial specifically examined what happens when patients
continue versus withdraw from tirzepatide after initial weight loss. Patients who continued the medication maintained their weight loss
substantially better than those who switched to placebo. Patients who stopped regained weight steadily over the following year.

 

Clinical decision-making for maintenance:

 

The choice of maintenance dose involves:

 

– Your weight loss outcomes on the higher dose
– Side effect tolerance
– Cost considerations
– Your stability of weight at goal
– Other clinical factors (e.g. diabetes control, cardiovascular risk)

 

This is not a one-size-fits-all decision. At Live Well Weight Loss, the maintenance conversation typically begins as patients approach their goal weight, not after they’ve stopped. We support patients through the transition, including monitoring weight, adjusting doses if needed, and providing ongoing pharmacist contact.

 

What about tapering off Mounjaro?

Mounjaro doesn’t require formal pharmacological tapering — there’s no withdrawal syndrome and no medical risk to stopping abruptly. However, many patients find a gradual reduction helpful for two reasons:

 

1. Reduced side effect rebound Some patients experience digestive changes when stopping abruptly — increased appetite, altered stool patterns, or rebound nausea. Tapering can soften this transition.

2. Easier behavioural adjustment Stepping down through dose levels gives more time to adjust eating habits, recognise hunger cues returning, and implement maintenance strategies before treatment is fully stopped.

 

A typical taper might look like:

 

– Reduce from 15mg to 10mg for 4–8 weeks
– Reduce to 7.5mg for 4–8 weeks
– Reduce to 5mg for 4–8 weeks
– Either stop or continue indefinitely on 5mg as a maintenance dose

 

This is not a clinical requirement — it’s a practical strategy. Many patients also stop without tapering and manage well with appropriate behavioural support.

The decision should be made in conversation with your prescriber based on your circumstances, goals, and how confident you feel about maintaining weight without medication.

 

How to minimise weight regain after stopping

If you do decide to stop Mounjaro entirely, several strategies can reduce the likelihood and pace of weight regain:

Maintain protein intake. Protein is the most satiating macronutrient and helps preserve lean muscle during and after weight loss. Aim for adequate protein at every meal — this becomes especially important without medication-driven satiety.

Continue resistance training. Muscle mass affects resting metabolic rate. Regular resistance training during and after weight loss helps preserve
muscle and can offset some of the metabolic adaptation that drives regain.

Monitor weight regularly. Weekly or bi-weekly weighing allows you to catch upward drift early, when it’s still small and easier to address. Many patients who succeed in long-term maintenance use regular self-monitoring.

Plan for the appetite return. Anticipate that hunger will increase weeks after stopping. Have strategies in place — meal structure, food choices,
activity levels — that don’t rely on the medication’s appetite suppression.

Consider periodic check-ins. Some patients benefit from staying in touch with their prescriber after stopping, with check-ins at 3, 6, and 12 months. This allows early intervention if weight regain begins.

Plan for treatment cycles if needed. If you stop and regain meaningful weight, restarting Mounjaro is a clinical option, not a failure. Some
patients use the medication in cycles, with treatment phases interspersed with maintenance phases. This should be discussed with a prescriber.

Address underlying drivers. For many patients, weight is influenced by stress, sleep, hormonal factors, or mental health. Addressing these alongside medication and after stopping it improves long-term outcomes.

Have a question first?

Want help planning your maintenance phase?

Live Well Weight Loss supports patients through the full treatment journey — including stepping down to maintenance, planning discontinuation, or restarting if weight regain begins. Place an order online to begin a clinical conversation, or contact our team to discuss your specific situation.

Place an Order
Contact Us 

What is a maintenance dose and how does it work?

A maintenance dose is a lower dose of Mounjaro continued after the initial weight loss phase. Rather than stopping treatment entirely, you remain on a reduced dose to preserve appetite control and prevent regain.

 

Typical maintenance approaches:

– 5mg maintenance: many patients can maintain at this dose with adequate appetite control and lower cost
– 7.5mg maintenance: a middle ground that retains stronger appetite suppression
– Step-down from a higher dose: some patients gradually reduce from their treatment dose over months

 

What the evidence shows:

 

Long-term trial data on tirzepatide maintenance is still emerging in 2026. The SURMOUNT-4 trial specifically examined what happens when patients
continue versus withdraw from tirzepatide after initial weight loss. Patients who continued the medication maintained their weight loss
substantially better than those who switched to placebo. Patients who stopped regained weight steadily over the following year.

 

Clinical decision-making for maintenance:

 

The choice of maintenance dose involves:

 

– Your weight loss outcomes on the higher dose
– Side effect tolerance
– Cost considerations
– Your stability of weight at goal
– Other clinical factors (e.g. diabetes control, cardiovascular risk)

 

This is not a one-size-fits-all decision. At Live Well Weight Loss, the maintenance conversation typically begins as patients approach their goal weight, not after they’ve stopped. We support patients through the transition, including monitoring weight, adjusting doses if needed, and providing ongoing pharmacist contact.

 

What about tapering off Mounjaro?

Mounjaro doesn’t require formal pharmacological tapering — there’s no withdrawal syndrome and no medical risk to stopping abruptly. However, many patients find a gradual reduction helpful for two reasons:

 

1. Reduced side effect rebound Some patients experience digestive changes when stopping abruptly — increased appetite, altered stool patterns, or rebound nausea. Tapering can soften this transition.

2. Easier behavioural adjustment Stepping down through dose levels gives more time to adjust eating habits, recognise hunger cues returning, and implement maintenance strategies before treatment is fully stopped.

 

A typical taper might look like:

 

– Reduce from 15mg to 10mg for 4–8 weeks
– Reduce to 7.5mg for 4–8 weeks
– Reduce to 5mg for 4–8 weeks
– Either stop or continue indefinitely on 5mg as a maintenance dose

 

This is not a clinical requirement — it’s a practical strategy. Many patients also stop without tapering and manage well with appropriate behavioural support.

The decision should be made in conversation with your prescriber based on your circumstances, goals, and how confident you feel about maintaining weight without medication.

 

How to minimise weight regain after stopping

If you do decide to stop Mounjaro entirely, several strategies can reduce the likelihood and pace of weight regain:

Maintain protein intake. Protein is the most satiating macronutrient and helps preserve lean muscle during and after weight loss. Aim for adequate protein at every meal — this becomes especially important without medication-driven satiety.

Continue resistance training. Muscle mass affects resting metabolic rate. Regular resistance training during and after weight loss helps preserve
muscle and can offset some of the metabolic adaptation that drives regain.

Monitor weight regularly. Weekly or bi-weekly weighing allows you to catch upward drift early, when it’s still small and easier to address. Many patients who succeed in long-term maintenance use regular self-monitoring.

Plan for the appetite return. Anticipate that hunger will increase weeks after stopping. Have strategies in place — meal structure, food choices,
activity levels — that don’t rely on the medication’s appetite suppression.

Consider periodic check-ins. Some patients benefit from staying in touch with their prescriber after stopping, with check-ins at 3, 6, and 12 months. This allows early intervention if weight regain begins.

Plan for treatment cycles if needed. If you stop and regain meaningful weight, restarting Mounjaro is a clinical option, not a failure. Some
patients use the medication in cycles, with treatment phases interspersed with maintenance phases. This should be discussed with a prescriber.

Address underlying drivers. For many patients, weight is influenced by stress, sleep, hormonal factors, or mental health. Addressing these alongside medication and after stopping it improves long-term outcomes.

Common reasons patients stop Mounjaro

Patients stop Mounjaro for various reasons, and the right approach depends on why they’re stopping:

 

Reached goal weight The most positive reason to stop. The challenge is maintaining the loss long-term. A structured maintenance plan is usually advisable.

 

Cost concerns Many patients stop because ongoing treatment is financially difficult. Stepping down to a lower maintenance dose can reduce cost while preserving most benefits. Discussing cost concerns with the prescriber may identify options.

 

Side effects Persistent side effects sometimes lead to discontinuation. In some cases, switching to Wegovy (semaglutide) or another medication can provide ongoing benefit with different side effect characteristics. This should always be a clinical discussion.

 

Pregnancy planning Mounjaro must be stopped before pregnancy, with a recommended washout period before conception. Patients planning pregnancy should discuss timing with a prescriber.

 

Other medication changes Starting other medications, planned surgery, or changes in medical condition can prompt stopping. These changes warrant a clinical conversation rather than abrupt cessation.

 

Personal preference or fatigue with treatment Some patients simply want a break from injections or feel ready to maintain their weight without medication. This is a valid reason but should be approached deliberately, with realistic expectations about the
regain risk.

 

What happens if you regain weight after stopping?

Regaining weight after stopping is common and not a failure. Several options exist:

 

Restart Mounjaro

Restarting is straightforward but requires re-titration from the lowest dose. The body needs to readjust to the medication, and side effects during early titration may return. The phased dose increase typically takes 2–4 months to reach the previous treatment level.

 

Switch to a different medication

Some patients restart with Wegovy or another GLP-1 medication rather than returning to Mounjaro. The clinical reasoning depends on the patient’s
circumstances.

 

Continue on a lower maintenance dose

If you stopped and regained, restarting on a maintenance dose (rather than the previous treatment dose) may be appropriate if regain is moderate. This is a clinical decision.

 

Address other factors

Sometimes weight regain reflects changes in life circumstances, mental health, or other medical issues. Restarting medication may not be the right first step in these cases — a broader assessment is more appropriate.

The decision about how to handle regain should always involve a prescriber. Restarting medications without clinical assessment is unsafe and not appropriate even for patients who have used them previously.

 

 

Frequently asked questions

Will I regain all the weight if I stop Mounjaro?

Trial data suggests average regain is about half of weight lost within a year of stopping, but individual outcomes vary widely. Patients with strong lifestyle support, regular self-monitoring, and continued behavioural change can maintain more of their loss. Patients without these supports often regain most or all of it.

Can I stop Mounjaro suddenly or do I need to taper?

There’s no medical requirement to taper – Mounjaro can be stopped at any point without withdrawal effects. Many patients find a gradual reduction more comfortable, but this is a practical preference rather than a clinical necessity.

How long can I stay on Mounjaro?

Mounjaro is licensed for chronic weight management and there is no fixed time limit on treatment. Long-term safety data continues to accumulate, and indefinite treatment is appropriate for many patients. The decision to continue, step down, or stop should be reviewed regularly with your prescriber.

Start your Mounjaro journey now.

If I stop and regain weight, can I just restart at my previous dose?

No. Restarting Mounjaro always begins at the lowest dose (2.5mg) and titrates upward over months. Restarting at a higher dose can cause severe side effects because the body needs to readjust to the medication.

Is a maintenance dose cheaper than a treatment dose?

Generally yes, because lower doses are priced lower. Maintenance doses (typically 5mg or 7.5mg) are less expensive than treatment doses (10mg, 12.5mg, 15mg) at most UK providers, and lower-dose pens last longer
between refills in some pricing models.

Can I switch to Wegovy when stopping Mounjaro?

Yes, switching from Mounjaro to Wegovy is possible. This is sometimes used as a step-down approach since Wegovy provides ongoing GLP-1 effect at a different intensity, or as a maintenance strategy after weight loss on Mounjaro. The switch should be planned with a prescriber.

Does the NHS support people stopping or maintaining on Mounjaro?

NHS specialist weight management services typically provide structured support for both treatment and discontinuation phases. NHS primary care access via the GP contract is a newer pathway and discontinuation support varies by local commissioning. Private pharmacies vary widely in their support for the maintenance and discontinuation phases.

How does Live Well Weight Loss support patients through this phase?

We support patients across the full treatment journey, including the transition to maintenance dosing, planned discontinuation, and restarting if needed. As your weight loss progresses, your pharmacist will discuss options with you and adjust the plan based on your goals. There’s no separate fee for maintenance support — it’s part of how the service works.

Sources & references

1. NICE Technology Appraisal TA1026 — Tirzepatide for managing overweight and obesity.

2. SURMOUNT-4 Trial — Continued treatment with tirzepatide for maintenance of weight reduction. JAMA, 2024.

3. STEP-4 Trial — Effect of continued weekly semaglutide vs placebo on weight maintenance. JAMA, 2021.

4. Mounjaro Summary of Product Characteristics. 

5. MHRA Drug Safety Updates: GLP-1 receptor agonists.

6. NICE NG7 — Cardiovascular disease: risk assessment and reduction in different ethnic groups.

7. British National Formulary (BNF) — Tirzepatide entry. 

About this article: This content is provided for factual information only. Eligibility for Mounjaro, Wegovy and other weight loss injections is determined by a qualified prescriber following individual clinical assessment. This article does not constitute medical advice. Live Well Weight Loss is a GPhC-registered UK pharmacy (registration number 9012516). Registered address: Unit T3, Enterprise Centre, Ray Street, Huddersfield, HD1 6BL.

Scroll to Top